

Natalizumab (Tysabri®) – Re-defining Efficacy in Multiple Sclerosis – Data from Clinical Trials to Post-marketing Experience

David Bates

Professor of Clinical Neurology, Department of Neurology, The Institute of Neuroscience, Newcastle University

DOI: 10.17925/ENR.2009.04.02.58

Abstract

Multiple sclerosis (MS) is a chronic, disabling condition with severe clinical and social consequences. Current first-line disease-modifying treatments have limited efficacy and do not halt long-term disease progression in the majority of patients. Natalizumab (Tysabri®) is the only monoclonal antibody licensed for use in relapsing–remitting MS (RRMS). It is regarded by many neurologists as the most effective MS drug on the market today, and has the potential to re-define successful MS therapy. Its efficacy has been demonstrated both in large-scale clinical trials and in post-marketing settings. Beneficial effects include reduction of relapse rates and disease progression and magnetic resonance imaging (MRI) measures of disease activity. Natalizumab treatment has a substantial impact on patient quality of life. Moreover, patients have shown significant improvement following natalizumab treatment, making continuing clinical remission a realistic goal in MS for the first time. However, the benefits of natalizumab must be balanced against risk. Progressive multifocal leukoencephalopathy (PML) is a rare event associated with natalizumab treatment that may be minimised with a risk management plan to educate physicians on patient selection and management.

Keywords

AFFIRM, natalizumab, progressive multifocal leukoencephalopathy (PML), relapsing–remitting multiple sclerosis (RRMS), Tysabri

Disclosure: David Bates, acts as international adviser to Biogen Idec and other pharmaceutical companies on the role of therapy in multiple sclerosis.

Received: November 17, 2009 **Accepted:** January 8, 2010

Correspondence: David Bates, Department of Neurology, The Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP, UK. E: david.bates@ncl.ac.uk

Support: Editorial assistance was provided by James Gilbert at Touch Briefings and was funded by Biogen Idec.

Multiple sclerosis (MS) is a chronic, inflammatory and neuro-degenerative disease in which T cells cross the blood–brain barrier and attack the myelin sheath, initiating an inflammatory cascade. The results are plaques of demyelination, gliosis and axonal degeneration.¹ It is the leading cause of non-traumatic disability among young adults, with a total estimated prevalence for the last three decades of 83 cases/100,000 population and an annual European incidence of 4.3 cases/100,000 population. The prevalence ratio of females to males is approximately 2:1² and may be increasing. The disease affects men and women in different ways, including age at onset, disease course and prognosis.³ Many geographical variations affect prevalence, including increased latitude both north and south of the equator.⁴ The onset of disease can span five decades, although it is most common between 20 and 30 years of age. The age at onset appears to affect prognosis, with younger patients generally taking longer to progress to a worse state of disability than older patients (progression to an Expanded Disability Scale Score [EDSS] of 4, at which walking is limited).⁵

MS results in significant disability: many patients are unable to walk unaided after a median of 15 years,⁶ and are wheelchair-bound by 25 years after disease onset.⁷ A number of variables have been shown to predict the time between onset of disease and onset of irreversible disability: gender, age, symptoms, disease course, degree of recovery from the first relapse, time to second neurological episode and number of relapses in the first five years of the disease. However,

these variables do not influence the subsequent progression of irreversible disability.⁵ In addition to physical disability, 43% of patients have some degree of cognitive dysfunction.⁸ The social costs of MS are high and include limited ability to participate in employment and perform routine household tasks, limited social functioning and increased psychopathology.⁹ MS is also a life-shortening disease, causing an average 10–12-year reduction in life expectancy.^{10,11} A study of deaths among MS patients found that complications from MS accounted for 47% of deaths, and the suicide rate was 7.5-fold higher than that for the age-matched general population.¹²

The clinical course of MS is heterogeneous, with variability both between and within patients, and has been categorised as secondary progressive MS (SPMS), primary progressive MS (PPMS) or relapsing–remitting MS (RRMS); the latter accounts for 85% of MS patients in the initial disease course. This article will focus on RRMS, which is characterised by relapses during which new symptoms may occur and old ones worsen, and remissions during which the patient fully or partially recovers from the deficits acquired during the relapse.¹³

Efficacy of Current First-line Disease-modifying Treatments

The formation of the inflammatory lesions that characterise MS is thought to be initiated by lymphocyte migration across the blood–brain barrier. This is mediated by adhesion molecules and ligands

Table 1: Comparison of Efficacy of Two-year Clinical Trials of Current First-line Disease-modifying Treatments in Multiple Sclerosis

Treatment Type	n	Dosage	Annual Relapse Rate		Disability Progression		Reference
			% Reduction	p-value	% Reduction	p-value	
IFNβ-1a	189 (560 total)	22µg SC 3 times a week	29	<0.005	23	<0.05	Galetta et al., 2002 ²¹
IFNβ-1a	184 (560 total)	44µg SC 3 times a week	32	<0.005	30	<0.05	Galetta et al., 2002 ²¹
IFNβ-1b	372	250µg SC every other day	34	0.0001	29	NS	IFNB, 1993 ¹⁸
IFNβ-1a	301	30µg IM once a week	32*	0.002	37	0.02	Jacobs et al., 1996 ¹⁹
Glatiramer acetate	251	20mg SC daily	29	0.007	12	NS	Johnson et al., 1995 ²⁰

*Calculated for patients who completed at least 104 weeks on study. IFN = interferon; IM = intramuscular; SC = subcutaneous; NS = not significant.


expressed on endothelial cells and leukocytes. The current disease-modifying treatments (DMTs) have multiple proposed mechanisms of action, including a possible effect on the interaction of one such adhesion molecule, $\alpha_4\beta_1$ integrin, with the ligand vascular cell adhesion molecule 1 (VCAM-1). Some DMTs have been observed to increase expression of VCAM-1 in active plaques in the brain and spinal cord, which may bind activated T cells, preventing them from crossing the blood–brain barrier.^{14–16} The existing treatments include the interferons beta IFNβ-1a (administered subcutaneously [SC], Rebif® or intramuscularly [IM], Avonex®) and IFNβ-1b (administered SC, Betaferon®). The precise mode of action of glatiramer acetate, also known as copolymer 1 (Copaxone®), is unknown: it may act as an immunomodulator or as a decoy, given its structural similarity to myelin. In clinical trials, all DMTs reduced the annualised relapse rate (ARR), but only IFNβ-1a (IM and SC) significantly reduced disability progression as determined by change in EDSS score compared with placebo^{17–21} (see Table 1). However, these treatments show only moderate efficacy and most patients still show disease progression. The majority (62–75%) of patients relapse within two years, and 20–27% of patients worsen by ≥ 1 point on EDSS within two years. Moreover, adherence to DMT treatment is problematic, largely due to side effects, particularly injection-site reactions and influenza-like symptoms. A chart-based study in Ireland on 394 MS patients determined an overall IFNβ stopping rate of 28% over five years.²² The study also showed a significant difference between the IFNβ stopping rates for RRMS (14%) and SPMS (23%) after three years ($p=0.0003$). Patients were shown to stop IFNβ due to side effects after a median of 13 months, and due to treatment failure after a median of 35 months ($p=0.0004$). Furthermore, many patients with MS have breakthrough disease activity despite therapy with these agents, or are unresponsive to treatment.²³ There is therefore a continuing and substantially unmet need for more effective treatments that limit relapses and disease progression within MS.

Natalizumab (Tysabri®) is a recently introduced recombinant humanised anti- α_4 -integrin antibody that is generally reserved for second-line use in MS, although it can be used as a first-line agent in cases of rapidly evolving severe RRMS.²⁴ The aim of this article is to review the broad spectrum of efficacy of natalizumab across traditional and non-traditional outcomes from clinical trials and post-marketing studies.

Mode of Action of Natalizumab

Natalizumab is the first α_4 -integrin antagonist in the class of selective adhesion molecule (SAM) inhibitors. It binds to α_4 -integrin on the surface of activated T cells, preventing adhesion between the T cell

Figure 1: Points Where Natalizumab Could Inhibit the Inflammatory Process in Multiple Sclerosis




VCAM = vascular cell adhesion molecule.

and the endothelial cell, thus disrupting the inflammatory cascade. It is a humanised monoclonal antibody to $\alpha_4\beta_1$ -integrin derived from a monoclonal antibody against human α_4 -integrin. Natalizumab has three putative modes of action (see Figure 1). It decreases leukocyte migration across the blood–brain barrier by blocking adhesion to endothelial cells and interaction with extracellular matrix (ECM) proteins, e.g. fibronectin. It also limits leukocyte priming and activation by blocking interaction with osteopontin and VCAM-1 expressed on microglial cells and monocytes in the brain parenchyma, and modulates leukocyte apoptosis by blocking interaction of α_4 -integrin-expressing leukocytes with ECMs. After a 300mg intravenous infusion of natalizumab, the elimination half-life is six to nine days, but α_4 -integrin receptors remain 80% saturated for approximately one month; therefore, administration is by monthly infusion.¹⁶

Data from Clinical Trials Supporting Natalizumab Use in Multiple Sclerosis

Two key large phase III clinical studies evaluating the clinical use of natalizumab involved a total of 2,113 patients and 3,804 patient-years

Figure 2: Annual Relapse Rate During AFFIRM and the Safety Extension



CI = confidence interval.
Source: O'Connor et al., 2006.²⁷

of exposure. The Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis (AFFIRM) study assessed natalizumab versus placebo treatment for 120 weeks in 942 patients with RRMS.²⁵ The SENTINEL study compared combined treatment with natalizumab and IFNβ-1a versus IFNβ-1a treatment alone for 120 weeks in 1,171 patients with RRMS.²³ The sample cohorts in both trials were large compared with previous trials of DMTs (see Table 1). Since natalizumab is currently only recommended as a monotherapy, this article will focus on the AFFIRM study.

The AFFIRM Study

The AFFIRM study was a large phase III clinical trial. Eligibility requirements were age 18–50 years, a diagnosis of RRMS, one or more documented clinical relapses within the prior 12 months, EDSS between 0 and 5.0 and having magnetic resonance imaging (MRI) lesions consistent with MS.²⁵ The primary end-points were the rate of clinical relapse at one year and the rate of sustained disability progression at two years, defined as an increase of 1.0 or more on the EDSS from a baseline score of 1.0 or more or an increase of 1.5 or more from a baseline score of 0 that was sustained for 12 weeks (progression could not be confirmed during a relapse). Patients were randomised to natalizumab 300mg (n=627) or placebo (n=315) by intravenous infusions every four weeks for up to 30 infusions. Neurological evaluations were carried out every 12 weeks, and proton-density-weighted or T₂-weighted and gadolinium-enhanced T₁-weighted MRI scans of the brain were performed at baseline and weeks 52 and 104. Patients had a mean age of 36.7 and 35.6 years and 67 and 72% were female in the placebo and natalizumab groups, respectively. Demographics and MS disease histories were similar between the two groups.

Natalizumab demonstrated substantial benefit over two years compared with placebo not only in the overall population but also in the subgroup of highly active patients, defined by at least two relapses in the previous year and at least one gadolinium-enhancing lesion at baseline. The rate of clinical relapse was reduced by 68% (p<0.001) in one year in the overall population, which was sustained at two years (see Figure 2), and by 81% (p<0.001) in the highly active population.²⁶ The risk of a sustained progression of disability (defined as EDSS progression sustained at 12 and 24 weeks) was reduced by 42–54% (p<0.001), and by 53–64% (p=0.029 and p=0.008) versus placebo in the highly active population. During an open-label extension study of

the AFFIRM trial, the low ARR was maintained and there was minimal progression in EDSS during the third year of natalizumab therapy.²⁷

Efficacy on MRI measures of disease activity was also demonstrated. Over two years, natalizumab reduced the mean number of new or enlarging T₂-hyperintense MRI lesions by 83% (p<0.001), and new lesions detected by gadolinium-enhanced MRI by 92% (p<0.001).

Within this trial, natalizumab had a good safety and tolerability profile: the only adverse events occurring significantly more frequently in the natalizumab group than in the placebo group were fatigue and allergic reaction. Hypersensitivity reactions were seen in 4% of patients receiving natalizumab, and serious hypersensitivity reactions in 1%.²⁵

Non-traditional Outcomes

Various *post hoc* analyses of the AFFIRM data have demonstrated risk reduction versus placebo in several non-traditional outcomes following natalizumab treatment. Natalizumab significantly improved health-related quality of life (HRQoL) based on Short Form-36 (SF-36) Physical and Mental Component Summary scores.²⁸ It also reduced visual loss assessed as low-contrast letter acuity testing by 35–47% (p≤0.008); such testing may act as a useful outcome measure in future clinical trials.²⁹ Over two years of treatment, natalizumab significantly lessened deterioration in ambulation, arm/hand function and cognitive function. In addition, natalizumab reduced the ARR requiring steroid use and the annualised rate of MS-related hospitalisations.³⁰ A new parameter for classifying disability progression, worsening of at least one Multiple Sclerosis Functional Composite component by 20% (MSFC-20) or 15% (MSDC-15), was evaluated using the AFFIRM data, and appears to be a sensitive and comprehensive assessment method.³¹

Re-defining Treatment Goals

Despite extensive therapy with current DMTs, most patients with MS continue to show disease activity and progression. Freedom from disease activity and improvement are the ultimate goals of treatment in inflammatory conditions, but to date this has not been considered attainable by MS clinicians.^{17–19}

A retrospective analysis of the AFFIRM data showed that in patients with a baseline EDSS ≥2, treatment with natalizumab significantly increased the probability of sustained improvement in disability (defined as a one-point decrease in EDSS score sustained for 12 weeks) by 69% relative to placebo (p=0.006). Those with highly active disease showed a 143% improvement over placebo (p=0.045).³² The mechanism of improvement is not yet understood. Preliminary data from post-marketing studies indicate that natalizumab promotes neuronal remyelination, particularly in RRMS, but further investigations are required to validate this finding.³³

Another recent analysis showed a 164% increase relative to placebo in freedom from clinical disease activity (p<0.0001, defined as absence of relapses and sustained clinical progression as measured by EDSS) and a four-fold increase over placebo in freedom from radiological disease activity (p<0.0001, defined as absence of gadolinium-enhancing lesions and absence of new or enlarging T₂-hyperintense lesions) over two years. When the results were expressed as a composite of clinical and radiological measures, the improvement in the treatment group was five-fold higher than that in the placebo group, suggesting that disease remission may become a realistic treatment goal in the future. In the highly active disease subgroup the proportion of

natalizumab-treated patients who were disease-free at two years represented a 16-fold improvement relative to placebo (see *Figure 3*). The effect of natalizumab treatment was greatest in the second year, indicating that efficacy may increase over time.³⁴


A long-term study followed up a subgroup of 23 MS patients who had previously been enrolled in two phase III trials evaluating natalizumab.³⁵ At 14 months after natalizumab treatment cessation, no clinical, radiographic or immunological rebound phenomena were observed. In addition, decreased lymphocyte numbers and altered cell ratios returned to normal during this period and no infectious complications were observed. These findings from a limited patient population suggest that disease recurrence and other complications may not be problematic, at least during the period of observation, after treatment with natalizumab.

The effects of stopping natalizumab were investigated by analysing data from a large-scale safety extension³⁶ that included patients who had participated in the AFFIRM study,²⁵ the SENTINEL study²³ and the GLatiramer Acetate and Natalizumab Combination Evaluation (GLANCE) safety study (a phase II study of natalizumab with glatiramer acetate versus placebo with glatiramer acetate in 110 patients with RRMS over 24 weeks).³⁷ The safety extension study was terminated early when dosing of natalizumab was voluntarily suspended following the report of two cases of PML in MS patients; the suspension of natalizumab dosing provided an opportunity to evaluate the effects of stopping therapy. The analysis included data from 946 original natalizumab patients who returned for safety evaluations after the voluntary suspension; these patients had received a mean 34.13±4.08 doses (range 6–41) before natalizumab was stopped. The data confirmed that, as would be expected based on natalizumab’s mechanism of action and pharmacodynamics, disease activity had returned to on-study placebo levels by four months following cessation of treatment. This return of disease activity, in terms of annual relapse rate, was similar in all clinical subgroups. Patients who had highly active disease before they were enrolled in the original studies showed a greater absolute increase in disease activity compared with those with less active MS. This was believed to be a result of the greater severity of the underlying disease process during the original studies. Disease activity following cessation of natalizumab did not rebound in excess of pre-existing disease activity levels. In addition, the use of other DMTs after stopping natalizumab did not appear to delay the return of disease activity, but this finding requires further confirmation in a larger patient population.³⁶

Post-marketing Experience

As of June 2009, natalizumab was approved in over 40 countries for the treatment of RRMS in patients who have an inadequate response to or are unable to tolerate another MS medication. It is also approved by the US Food and Drug Administration (FDA) in adult patients with moderately to severely active Crohn’s disease. By the end of September 2009, around 60,700 patients had been treated with natalizumab in the post-marketing setting.³⁸ An overview of post-marketing data from natalizumab patient registries and treated cohorts around the world, including effects on relapse rates and disability progression, is given in *Table 2*. These ‘real-world’ data show that, generally, patients being treated in the clinic are slightly older and have longer disease duration, higher EDSS and higher baseline ARR than patients recruited into clinical trials. Despite these baseline differences, patients treated with natalizumab in clinical practice showed stabilisation of disability and attenuation of

Figure 3: Proportions of Disease-free Patients Receiving Natalizumab or Placebo in the Overall and Highly Active Disease Populations



*Patients with ≥2 relapses in prior year and ≥1 Gd+ lesion at baseline. p<0.0001, natalizumab versus placebo for both overall and highly active patients. 5x: Expressing results as a composite of clinical and radiological measures, the improvement in the treatment group was five-fold over placebo. 16x: In the highly active disease subgroup, the proportion of natalizumab-treated patients who were disease-free at two years showed a 16-fold improvement over placebo. Source: Havrdova, 2009.³⁴

disease activity, which was comparable to observations in clinical trials. The proportion of patients discontinuing was similar across all four studies (8.2–15%), and the safety profile of natalizumab is similar to that seen in the AFFIRM study.²⁵ A health economic study on natalizumab in the UK concluded that the therapy is cost-effective compared with current DMTs in all patients with highly active RRMS.³⁹

Long-term Safety

Natalizumab was voluntarily withdrawn from the market one year after its FDA approval in 2004 following three confirmed cases of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain: in two patients from the SENTINEL study and in one patient with Crohn’s disease.^{40,41} The FDA and European Medicines Agency (EMA) re-approved the drug in 2006 with revised labelling, and it is now recommended only as monotherapy.⁴² Natalizumab is prescribed in the US through a risk minimisation programme that has mandatory enrolment. Patients and physicians are required to participate in the Tysabri Outreach: Unified Commitment to Health (TOUCH) programme, in which patients are screened for PML symptoms before each natalizumab infusion.⁴³ As of 30 November 2009, there have been 28 confirmed cases of PML in more than 60,000 Tysabri-treated patients in the post-marketing setting.³⁸ It should be noted that the absolute number of PML cases should be evaluated in the larger context of the number of patients actually exposed to natalizumab; it is therefore a less important measure than the incidence. In patients treated for up to three years, the risk of PML appears to increase with increasing treatment duration. In patients treated for two to three years, the rate of PML is consistent with that seen in pre-approval clinical trials. There is limited experience in patients who have received more than three years of Tysabri treatment.


The duration of natalizumab dosing prior to PML diagnosis ranged from approximately one year to more than 3.5 years (12–44 infusions), and the incidence of PML generally increases with duration of exposure, as shown in *Figure 4*. To date, clinical signs and symptoms that prompted evaluation for PML in natalizumab-treated patients

Table 2: Real-life Findings from Clinical Use of Natalizumab in Patient Registries and Cohorts Around the World

Patient Registry/Cohort Reference	n	Baseline ARR, EDSS	On-study ARR, EDSS	% Relapse-free	% Discontinuation
Danish registry ⁴⁶	234 ^a	2.53 (2.33–2.75) 4.0 (0–8) (median)	0.68 (0.57–0.81) N/A	63	15
Essen, Cologne, Erlangen, St Gallen cohort ⁴⁷	97 ^b	2.3±0.6 3.6±0.8 (mean)	0.17±0.1 3.2±0.8 (mean)	80	8.2
Nord-Alsace cohort ⁴⁸	384	2.19±1.23 3.53±1.68 (mean)	0.59± 0.84 ^c 3.02±1.73 ^c (mean)	60 ^c	9.1
Tysabri® Observational Program (TOP) cohort ⁴⁹	1,011	2.07±1.08 ^d 3.8±1.7 ^e	0.26 (0.22, 0.32) ^d 3.6±1.8 ^e (reduction: 0.2±0.97)	N/A	10.6 ^f

a. Proportion of patients with an EDSS 1.0-point progression 0.09, median observation period of 11.3 months (range 3–21.5); b. Mean treatment duration 19.3±6.1 months; c. Based on 127 patients observed for at least 1 year; d. Based on 587 patients observed for at least 6 months; e. Based on 292 patients observed for at least 12 months; f. Includes therapy discontinuation and study withdrawal. ARR = annualised relapse rate; EDSS = Expanded Disability Status Scale.

Figure 4: Natalizumab Progressive Multifocal Leukoencephalopathy Incidence Estimates Based on Patients Exposed and Treatment Duration



Diamonds represent estimated incidence, bars represent confidence intervals. Data updated 30 November 2009 based on 28 cases. Source: Hyde et al., 2009.³⁸

Table 3: The Multiple Long-term Programmes for Monitoring the Safety and Efficacy of Natalizumab in Clinical Use

Programme	STRATA	TOUCH	TYGRIS	TOP
Regulatory commitment	Yes (EU)	Yes	Yes	Yes (EU)
Interventional study (3b)	Yes	No	No	No
Mandatory prescribing programme	No	Yes	No	No
Observational programme	No	No	Yes	Yes
Efficacy data collection	Yes	No	No	Yes
Safety data collection	Yes	Yes	Yes	Yes
Number of patients	850	Unlimited	5,000	3,000
Duration (years)	5	Unlimited	5	5

STRATA = Safety of Tysabri Re-dosing And Treatment study; TOUCH = Tysabri Outreach: Unified Commitment to Health Prescribing Program; TYGRIS = Tysabri Global Observation Program in Safety observational cohort study; TOP = Tysabri Observational Program.

were new or worsening neurological symptoms evolving over several weeks, focal neurological signs and other symptoms, such as hemiparesis, focal myoclonia, aphasia, retrochiasmatal visual deficits and changes in cognition, behaviour and personality.

MRI assessments of PML cases typically revealed non-enhancing T₂-hyperintense lesions in frontal, temporal, parietal or occipital regions. Many of these lesions were unifocal, and gadolinium-enhancing lesions were identified. Analyses using polymerase chain reaction detected JC virus DNA in the cerebrospinal fluid of patients with PML. However, in most patients titres were low (<500 copies/ml). In PML not associated with natalizumab, new or worsening neurological signs or symptoms, changes in mental status, seizure or fever were usually not associated with gadolinium-enhancing lesions.³⁸

Natalizumab was discontinued when the first signs or symptoms and/or MRI findings suggestive of PML were identified. The majority of patients who developed PML in the post-marketing setting received plasma exchange and/or immunoadsorption to accelerate removal of natalizumab from circulation.

During recovery from PML, immune reconstitution recovery syndrome (IRIS) is an expected condition. This appears universal in PML associated with natalizumab, unlike PML in AIDS, regardless of whether natalizumab is removed rapidly or simply discontinued.⁴⁰ IRIS generally occurred four weeks after stopping natalizumab treatment, but in some cases it occurred earlier. Corticosteroids, sometimes multiple courses, given early in the course of IRIS appeared to lead to improvement in most patients. To date, most of the natalizumab-treated patients who developed PML have survived but exhibit varying levels of disability.³⁸

A quantitative risk–benefit analysis demonstrated that the substantial benefits of natalizumab, particularly in patients with highly active disease or those who do not respond to other DMTs, far outweigh the risk of PML.⁴⁴ At present, there are multiple long-term evaluation programmes in progress that are designed to further characterise the long-term safety and efficacy of natalizumab (see Table 3). There are currently insufficient data on the efficacy and safety of natalizumab in patients with progressive forms of MS to recommend the use of natalizumab for primary or secondary progressive MS.⁴⁵

Discussion

MS is a serious disease with devastating clinical and social consequences for which there is a great need for more effective

therapies. The high levels of efficacy demonstrated by natalizumab in clinical trials and post-marketing studies confirm its importance, and have enhanced the therapeutic outcome goals in MS. Natalizumab reduces measures of disease activity such as clinical relapse rate, gadolinium enhancement and new and enlarging T₂ lesions in patients with relapsing MS. It also improves measures of disease severity such as EDSS progression rate and T₁ and T₂ lesion burden detected by MRI in patients with RRMS. It has produced substantial improvements in health-related quality of life and physical and cognitive function. Its effect is particularly marked in those patients with highly active disease. Furthermore, natalizumab has been shown to bring about

sustained improvement in disability and an absence of disease activity, representing a new goal in MS therapy. However, the increased benefits of natalizumab have to be balanced with the risks. PML and other opportunistic infections are rarely seen. Physician and patient education plays a key role as early diagnosis of PML and early discontinuation of natalizumab in cases of suspicion might improve the outcome. Predictors of the risk of developing PML are currently being investigated. Since natalizumab has improved disease status even in patients with highly active MS, future clinical studies should assess the efficacy of MS treatments not only in slowing progression, but also in improving disability or achieving remission. ■

1. Goodin DS, Frohman EM, Garmany GP, et al., Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines, *Neurology*, 2002;58:169–78.
2. Pugliatti M, Rosati G, Carton H, et al., The epidemiology of multiple sclerosis in Europe, *Eur J Neurol*, 2006;13:700–722.
3. Schwendimann RN, Alekseeva N, Gender issues in multiple sclerosis, *Int Rev Neurobiol*, 2007;79:377–92.
4. Richards RG, Sampson FC, Beard SM, et al., A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models, *Health Technology Assessment*, 2002;6:(10).
5. Confavreux C, Vukusic S, Adeleine P, Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process, *Brain*, 2003;126:770–82.
6. Weinshenker BG, Bass B, Rice GP, et al., The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability, *Brain*, 1989;112(Pt 1):133–46.
7. Compstone A, *McAlpine's Multiple Sclerosis*, London: Churchill Livingstone, 1998.
8. Rao SM, Leo GJ, Bernardin L, et al., Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction, *Neurology*, 1991;41:685–91.
9. Rao SM, Leo GJ, Ellington L, et al., Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning, *Neurology*, 1991;41:692–6.
10. Ebers GC, Natural history of multiple sclerosis, *J Neurol Neurosurg Psychiatry*, 2001;71(Suppl. 2):ii16–19.
11. Sadovnick AD, Ebers GC, Wilson RW, et al., Life expectancy in patients attending multiple sclerosis clinics, *Neurology*, 1992;42:991–4.
12. Sadovnick AD, Eisen K, Ebers GC, et al., Cause of death in patients attending multiple sclerosis clinics, *Neurology*, 1991;41:1193–6.
13. Lublin FD, Reingold SC, Defining the clinical course of multiple sclerosis: results of an international survey, *Neurology*, 1996;46:907–11.
14. Calabresi PA, Tranquill LR, Dambrosia JM, et al., Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b, *Ann Neurol*, 1997;41:669–74.
15. Graber J, Zhan M, Ford D, et al., Interferon-β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis, *J Neuroimmunol*, 2005;161:169–76.
16. Rudick RA, Sandrock A, Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS, *Expert Rev Neurother*, 2004;4:571–80.
17. PRISMS Study and Group, Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group, *Lancet*, 1998;352:1498–1504.
18. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group, *Neurology*, 1993;43:655–61.
19. Jacobs LD, Cookfair DL, Rudick RA, et al., Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG), *Ann Neurol*, 1996;39:285–94.
20. Johnson KP, Brooks BR, Cohen JA, et al., Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group, *Neurology*, 1995;45:1268–76.
21. Galetta SL, Makowitz C, Lee AG, Immunomodulatory agents for the treatment of relapsing multiple sclerosis – a systematic review, *Arch Intern Med*, 2002;162:2161–9.
22. O'Rourke KE, Hutchinson M, Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns, *Mult Scler*, 2005;11:46–50.
23. Rudick RA, Stuart WH, Calabresi PA, et al., Natalizumab plus interferon beta-1a for relapsing multiple sclerosis, *N Engl J Med*, 2006;354:911–23.
24. Tysabri European Public Assessment Report (EPAR) Revision 6, 18 June 2009. Available at: www.emea.europa.eu/humandocs/Humans/EPAR/tysabri/tysabri.htm
25. Polman CH, O'Connor PW, Havrdova E, et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis, *N Engl J Med*, 2006;354:899–910.
26. Hutchinson M, Kappos L, Calabresi PA et al., The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL, *J Neurol*, 2009;256(3):405–15.
27. O'Connor PW, Goodman A, Kappos L, et al., The safety and tolerability of natalizumab: results from the safety-extension study in patients with multiple sclerosis, Paper presented at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Madrid, Spain, 29 September 2006.
28. Rudick RA, Miller D, Hass S, et al., Health-related quality of life in multiple sclerosis: effects of natalizumab, *Ann Neurol*, 2007;62:335–46.
29. Balcer LJ, Galetta SL, Calabresi PA, Natalizumab reduces visual loss in patients with relapsing multiple sclerosis, *Neurology*, 2007;68:1298–1304.
30. Phillips JT, O'Connor PW, Havrdova E, et al., The Effects of Natalizumab on Clinical Measures of Efficacy in MS, 20th Consortium of Multiple Sclerosis Centers (CMSC) Conference, Scottsdale, Arizona, 2006, abstract S61.
31. Rudick RA, Polman CH, Cohen JA, et al., Assessing disability progression with the Multiple Sclerosis Functional Composite, *Mult Scler*, 2009; 15: 984–997.
32. Munschauer F, Giovannoni G, Lublin F, et al., Natalizumab significantly increases the cumulative probability of sustained improvement in physical disability, *Mult Scler*, 2008;14:S167–8 (P474).
33. Zivadinov R, Dwyer MG, Bergsland N, et al., Natalizumab (Tysabri®) Promotes Remyelination in Patients with Multiple Sclerosis. A Voxel-Wise Magnetization Transfer Imaging Case-Control Study, Proceedings of the 61st Annual Meeting of the American Academy of Neurology, 2009, P03.071.
34. Havrdova E, Galetta S, Hutchinson M, et al., Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study, *Lancet Neurol*, 2009;8:254–60.
35. Stüve O, Cravens PD, Frohman EM Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy, *Neurology*, 2009;72(5):396–401.
36. O'Connor PW, Goodman AD, Kappos L, et al., Return of Disease Activity After Cessation of Natalizumab Therapy in Patients with Multiple Sclerosis, Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Düsseldorf, Germany, 9–12 September 2009.
37. Goodman AD, Rossman H, Bar-Or A, et al., GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study, *Neurology*, 2009;72(9):806–12.
38. Hyde R, Bozic C, Belcher G, et al., Utilization and safety of natalizumab in patients with relapsing Multiple Sclerosis in the post-marketing setting, Presented at the 19th World Congress of Neurology, Bangkok, Thailand, 24–30 October 2009, Presentation FP33-WE-04.
39. Gani R, Giovannoni G, Bates D, et al., Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK, *Pharmacoeconomics*, 2008;26:617–27.
40. Langer-Gould A, Atlas SW, Green AJ, et al., Progressive multifocal leukoencephalopathy in a patient treated with natalizumab, *N Engl J Med*, 2005;353:375–81.
41. Kleinschmidt-DeMasters BK, Tyler KL, Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis, *N Engl J Med*, 2005;353:369–74.
42. Tysabri prescribing information, Biogen Idec, Inc., 2006. Available at: www.tysabri.com/en_US/tysab/site/pdfs/TYSABRI-pi.pdf
43. Baker DE, Natalizumab: overview of its pharmacology and safety, *Rev Gastroenterol Disord*, 2007;7:38–46.
44. Thompson JP, Noyes K, Corsey ER, et al., Quantitative risk-benefit analysis of natalizumab, *Neurology*, 2008;71(5):357–64.
45. Kappos L, Bates D, Hartung H-P, et al., Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring, *Lancet Neurol*, 2007;6:431–41.
46. Oturai AB, Koch-Henriksen N, Petersen T, et al., Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study, *Eur J Neurol*, 2009;16(3):420–23.
47. Putzki N, Yaldizli O, Mäurer M, et al., Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries, *Eur J Neurol*, 2010;17:31–7.
48. Outteryck O, Ongagna JC, Zéphir H, et al., Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice, *J Neurol*, 2009 Aug 27 (published online).
49. Wiendl H, Butzkueven H, Trojano M, et al., TYSABRI® Observational Program (TOP): Assessment of Long-term Safety and Impact on Disease Activity and Progression of TYSABRI (natalizumab) in Patients with Relapsing Remitting MS, Presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Düsseldorf, Germany, 9–12 September 2009, poster P814.